Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 14/20 | 0.45 |
| ▸ | AKT2 | P31751 | 14/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416906 | 0.89 | AKT1 (0.43) | AKT1AKT2SMN1; SMN2 | |
| SCHEMBL4422230 | 0.79 | PTK2 (0.44) | GRM2FGFR1PDGFRBSRCPDGFRA | |
| SCHEMBL4418885 | 0.79 | AKT1 (0.37) | AKT1AKT2FGFR1KDM4E | |
| SCHEMBL3870552 | 0.76 | AKT1 (0.44) | AKT1AKT2FGFR1PDGFRBSRC | |
| SCHEMBL3867128 | 0.73 | RXFP1 (0.44) | AKT1AKT2 | |
| SCHEMBL4423148 | 0.73 | RIPK2 (0.49) | AKT2FGFR1PDGFRBSRCCDK2 | |
| SCHEMBL4413304 | 0.73 | IKBKB (0.49) | CDK2 | |
| SCHEMBL4422231 | 0.72 | AKT1 (0.36) | AKT1AKT2 | |
| SCHEMBL4414517 | 0.70 | MEN1 (0.40) | AKT1AKT2MAPT | |
| SCHEMBL4420761 | 0.69 | PKMYT1 (0.40) | FGFR1PDGFRBSRCPDGFRACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | LCK, TYRO3, ABL1 | AKT1 540/4885AKT2 593/4885GRM2 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.